Youmai Technology Secures $10M Series A+ Financing Led by Matrix Partners China to Build a Digital Dermatology Healthcare Ecosystem

VCBeat has learned that Umai Technology, China’s leading value platform for dermatologists, recently announced the completion of its multi-million-dollar Series A+ financing round. The round was exclusively invested by Matrix Partners China, with Haoyue Capital serving as the exclusive financial advisor.

Founded in 2015, Umai Technology has become one of the most influential value platforms for dermatologists in China. Its core product, the Umai Doctor APP, has accumulated over 100,000 users, covering more than 95% of dermatologists nationwide. It is officially recognized by professional institutions such as the Dermatologist Branch of the Chinese Medical Doctor Association, the Dermatology and Venereology Branch of the Chinese Medical Association, and the Dermatology and Venereology Professional Committee of the Chinese Association of Integrative Medicine as one of the most professional learning platforms for dermatologists in China. Meanwhile, the company operates across the high-potential healthcare and consumer sectors, providing professional one-stop digital marketing solutions to hundreds of pharmaceutical companies specializing in dermatology and skincare consumer goods companies. This round of financing will drive Umai Technology to further strengthen its efforts in building specialized internet hospitals and managing disease-specific patient journeys, thereby constructing a closed-loop ecosystem for digital dermatological healthcare centered on an integrated doctor-patient strategy.

Youmai Doctor App — China's Leading Learning Platform for Dermatologists

In recent years, innovative therapies for major dermatological indications have emerged in rapid succession. Biologics such as Cosentyx, Taltz, Tremfya, Skyrizi, and Dupixent have demonstrated unstoppable global sales momentum. Since their sequential launch in China starting in 2019, these agents have filled previous therapeutic gaps in the domestic market. Against this backdrop, digital marketing has become an essential strategy for dermatology pharmaceutical companies to enable innovative biologics to reach physicians with precision and efficiency, facilitate educational promotion, and achieve rapid market penetration.

According to statistics, the market for innovative dermatological drug therapies, with primary indications including psoriasis, atopic dermatitis, herpes zoster, and androgenetic alopecia, is expected to drive nearly RMB 7 billion in digital marketing spending by 2025. Meanwhile, the efficacy-based skincare market, valued at over RMB 100 billion, will generate even more substantial digital marketing investment, conservatively projected to reach nearly RMB 35 billion in 2025.

For many years, Youmai Technology has“D+B+C”model serves dermatologists and collaborates with over a hundred innovative pharmaceutical companies and skincare brands in the dermatology field:

In 2021, Umai Technology further iterated and upgraded its “D+B+C” integrated digital marketing strategy. In terms of content strategy, Umai Technology partnered with the National Clinical Research Center for Skin and Immune Diseases to establish the Umai Health Education College under the National Clinical Center, which is currently buildingNational Online Learning, Training, and Assessment System for Dermatologists, and it plans to collaborate with high-traffic platforms such as Kuaishou, Douyin, and DXY Doctor to jointly establish an “industry evaluation system for skincare science popularization.” The U+ Alliance, a coalition of science-focused physicians under Youmai Technology, has already gathered more than 600 dermatologists dedicated to consumer-facing science communication. The U+ Alliance is committed to partnering with leading traffic platforms and professional MCN agencies to build premier dermatologist IPs, foster resonance between the medical community and the general public, and help physicians enhance their brand value.

In leading industry transformation, Umai Technology has partnered with the National Clinical Research Center for Skin and Immune Diseases to establish the Cosmetic Scientific Evaluation Support Committee. Starting with the standardized interpretation of new regulations on cosmetic efficacy claims, the committee is committed to empowering the healthy development of China’s functional cosmetics industry.

In terms of patient services, in April 2021, Youmai Technology officially obtainedInternet Hospital License, thousands of dermatologists are joining in successionYoumai Cloud Hospital, jointly promote the popularization of dermatological knowledge to a broader audience, and provide a scientific, intelligent, and precise comprehensive solution for national skin health care.

UMAI Cloud Hospital — One-Stop Smart Skin Management Platform

Mr. Chang Jiang, Founder of Youmai Technologystated, “We have always adhered to our mission of ‘improving skin health through technological innovation’ and continuously expanded our business around the goal of ‘building a digital healthcare ecosystem for dermatology.’ Today, we have become a professional platform-based company in the field of dermatology, covering the ‘D+B+C’ (Doctor, Business, Consumer) sectors. As a specialty closely linked to the consumer market, dermatology spans multiple sub-sectors, including prescription drugs, over-the-counter (OTC) medications, functional skincare products, and medical aesthetics, offering immense growth potential. With the trust and strong support of investors and partners, this round of financing was completed smoothly and efficiently. Moving forward, Youmai will continue to focus on the physician value system, strengthening the company’s professional barriers and its attributes as a technology service platform. Rooted in healthcare, we aim to gradually build a one-stop smart skin management platform that provides science education, consultation services, and skin health record management for consumers, delivering intelligent skin solutions that combine precise medication with professional, medical-grade skincare. We look forward to realizing our vision at an early date: making the Youmai Index the standard skincare index for the Chinese population.”

Mr. Sun Linghao, Investment Director at Matrix Partners ChinaIt was stated that the skin is the largest organ of the human body, with clear unmet needs among consumer-end users. Over the past two years, the supply side has witnessed a surge in both dermatological/autoimmune drugs and cosmeceuticals. Communicating their medical and health value requires professional, precise digital outreach. Leveraging the Youmai Doctor App, which covers 95% of dermatologists, Youmai has established an industry-leading “D+B+C” platform for dermatology. We anticipate Youmai will evolve into the foundational infrastructure for the skin health and medical industry.

Mr. Guo Yixin, Vice President of Haoyue CapitalIt was stated that digital healthcare marketing has witnessed rapid growth amid the pandemic. Haoyue Capital has made in-depth investments in companies within this sector, focusing not only on leading generalist platforms but also deeply cultivating dominant players in specialized verticals. Dermatology is one of the medical specialties with the strongest consumer attributes; the market for functional skincare products has been well-educated, while innovative dermatological therapies are entering a golden age. Since its inception, Umai’s founding team has remained dedicated to the dermatology vertical. By leveraging high-quality academic content, it has established authoritative influence in the field. Its extensive brand resources and MCN (Multi-Channel Network) operational capabilities empower dermatologists to pursue continuous learning and self-improvement, while exploring greater opportunities for market engagement and realizing their personal value. We are honored to partner with Umai in completing this round of financing, witnessing the company gain recognition from both its user base and the capital markets.

Matrix Partners China, established in 2008, is a leading venture capital firm in China. Over the past decade since its inception, it has remained deeply rooted in the local market, steadfastly investing in Chinese entrepreneurs. Matrix Partners China has invested in more than 700 companies to date. Notable portfolio companies include Didi Chuxing, XPeng Motors, Li Auto, Futu Securities, Chehaoduo Group, Youzan, Ronbay Technology, XGIMI Technology, Momo, Ele.me, Peijia Medical, Kemei Diagnostics, Genor Biopharma, Career International, LexinFintech, So-Young, Yuanfudao, PingCAP, Zihai Guo, Simple Love, i-Space, Taimei Medical Technology, and Drug Research Club.

Haoyue Capital, established in January 2014, is committed to serving as a bridge connecting China’s healthcare industry with capital. Its research and transaction coverage spans multiple sub-sectors, including biopharmaceuticals, innovative medical devices, in vitro diagnostics (IVD) and precision medicine, healthcare services, and smart healthcare. The Haoyue Capital team comprises senior investment bankers with extensive experience in China’s healthcare sector. By closely monitoring market dynamics and investment trends in healthcare over the long term, the firm releases weekly healthcare investment newsletters and thematic research reports, offering Haoyue’s perspectives on new policies and emerging frontiers.